# Ranok Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ranok-therapeutics

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.ranoktherapeutics.com
- Total disclosed funding: $40M
- Latest round: Series B (Aug 18, 2021)
- Investors on record: 6

## About

Established in 2018 and based in Hangzhou, China, Ranok Therapeutics is a biotechnology company that engages in research and development of cancer treatment drugs. The company's founder and CEO, Weiwen Ying, formerly worked at Synta Pharmaceuticals and was the co-founder and president of Capten Therapeutics. He has more than 19 years of industry experience in medicinal chemistry, drug discovery, preclinical and clinical development.

The company mainly develops chaperone-mediated Protein Degradation/Degrader (CHAMP) technology, which uses different underlying biological processes from other targeted protein degradation methods (such as PROTAC) and has many unique advantages, including the use of tumor tissue targets To improve the safety of drugs.

## Funding rounds

- Series B, Aug 18, 2021, $40M — Zhongguancun Venture Capital, Wu Capital, Shanghai Industrial Investment (Holdings), MED-FINE Capital, Lapam Capital, LC Ventures

## Investors

- Zhongguancun Venture Capital (https://capitalatlas.ai/funds/zhongguancun-venture-capital) — Series B
- Wu Capital — Series B
- Shanghai Industrial Investment (Holdings) — Series B
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series B
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series B
- LC Ventures (https://capitalatlas.ai/funds/lc-ventures) — Series B